Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3183159 A
Publication typeGrant
Publication dateMay 11, 1965
Filing dateMar 20, 1962
Priority dateMar 20, 1962
Publication numberUS 3183159 A, US 3183159A, US-A-3183159, US3183159 A, US3183159A
InventorsSingher Heron O, Wellerson Jr Ralph
Original AssigneeOrtho Pharma Corp
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Stabilized partial thromboplastin reagent
US 3183159 A
Abstract  available in
Images(2)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent M 3,183,159 STABILIZED PARTIAL THROMBOPLASTIN REAGENT Heron 0. Singher, Plainfield, and Ralph Wellerson, Jr.,

Bound Brook, N.J., assignors to Ortho Pharmaceutical Corporation, a corporation of New Jersey No Drawing. Filed Mar. 20, 1962, Ser. No. 181,202

6 Claims. (Cl. 167-74) The present invention relates to a method of stabilizing partial thrombop'lasti'n reagent and to the stabilized partial thromboplastin reagent so obtained.

The partial thromboplastin time testwas originally developed by Langdell, Wagner and Brinkhous as a method of following the therapy of hemophilic patients. These investigators found this test to be extremely sensitive to changes in Factor VIII brought about by whole blood or plasma transfusions. Extensive studies of the partial thromboplastin timetest by Rodman, Barrow and Graham have shown that this test is sensitive to plasma deficiencies of Factor II (Prothrombin), Factor V (AcG, Labile Factor), Factor VIII, Factor IX (PTC), Factor X (Stuart Prower Factor), Factor XI (PTA), and Factor XII (Hageman Factor). In patients deficient in any of the above factors prolonged partial thromboplastin time values are obtained. However, the partial thromboplastin test has not been generally employed as widely as might be warranted for the reason that the partial thromboplastin reagent must be freshly prepared and standardized just prior to use or else prepared in a dry form necessitating reconstitution.

It is an object of the present invention, therefore, to provide a partial thromboplastin reagent that will remain stable in the liquid form upon storage over an extended period of time so that accurate results will be obtained irrespective of the time that the reagent is used.

It has now been discovered that a partial thromboplastin test reagent may be stabilized by the addition to the reagent of small quantities of sodium ethylmercurithiolsalicylate having the formula:

When present at a concentration of 1 part in 10,000 (0.01%), the sodium ethylmercurithiolsalicylate acts as an effective stabilizing agent without effecting the activity of the partial thromboplastin reagent or altering the partial thromboplastin time. Larger amounts of the sodium ethylmercurithiolsalicylate are no more effective in stabilizing the partial thromboplastin reagent and it is recommended that greater concentrations of this sodium salt (more than 0.01%) be avoided as the mercury ion in higher concentrations could interfere with the partial thromboplastin test. The addition of appreciably smaller quantities of sodium ethylmercurithiolsalicylate (less than 0.001%) should also be avoided as too little a quantity of sodium ethylmercurithiolsalicylate may not provide the desired stability under all conditions of storage.

In order that those skilled in the art may better understand how the present invention may be carried out, the following examples are given by way of illustration an not by way of limitation.

3,183,159 Patented May 11, 1965 EXAMPLE 1' Preparation of partial thromboplastin reagent The stable partial thrombopla-s tin reagent of the present invention is an ether extract of acetone dried brain tissue. Bovine brain is used as the starting material. The meninges are removed, and the brain is washed under tap water; About 100 grams of wet brain are covered with acetone and allowed to stand for 1 hour. The tissue is gefitly mashed under acetone in a mortar with a pestle. The supernatant is decanted and discarded and the process repeated until the tissue becomes flaky and the acetone remains clear. The tissue is then ground into small particles and spread on a flat pan to dry. The yield of dry powder so obtained is 18 grams. The 18 grams of dry brain powder (in an Erlenmeyer flask) is covered with ether, and stoppered. The dry-material is suspended by shaking and allowed to stand overnight at room temperature. The following morning, the supernatant is filtered until clear, and the clear filtrate evaporated to dryness with a stream of air. The dry residue is washed twice with 40 ml. boiling acetone, then air-dried. This residue (cephalin) is a pale yellow waxy material and weighs 3.0 grams. This material is suspended in 3 ml. of physiological saline, and the volume brought to 100 ml. by the slow addition of physiological saline with careful mixing. The 3 percent suspension so obtained is opaque and white in color.

One gram of sodium ethylmercurithiolsalicylate is dissolved in 10,000 grams of physiological saline, and 1,900 ml. of the solution so obtained is added with stirring to the 3% suspension of cephalin (100 ml.) described above. The diluted suspension is sealed in vials and may be stored indefinitely at 5 C. without loss of activity. This product may be used as a reagent in running the partial thromboplastin test.

EXAMPLE II The partial thromboplastin test Human blood samples are collected using as an anticoagulant a 0.1 M aqueous solution of sodium oxalate. The anticoagulant is added to the blood in the proportion of one part by volume anticoagulant to nine parts by volume of blood. The blood is then centrifuged and the plasma is separated.

The human blood plasma, 0.1 ml., collected as de scribed above, is placed in a 10 x mm. test tube. To this is added 0.1 ml. of the partial thromboplastin test reagent prepared as described in Example I above, and the test tube is placed in a water bath heated to 37 C. for 30 seconds. Calcium chloride solution is then added to the test tube (0.1 ml. of 0.02 CaCl and a stop watch is started. The tube is tapped gently 2 or 3 times to mix the materials and placed in the water bath until the stop watch reads 60 seconds. The test tube is then removed from the water bath and gently tilted until a clot forms. The stop watch is stopped at this point and the elapsed time is recorded as the partial thromboplastin time. The test is performed both on a control and patients plasma. The normal range is 60 to seconds.

EXAMPLE III Two lots of partial thromboplas'tin reagent prepared as described in Example I above, but at different times, are tested immediately after their preparation with normal human plasma. The partial thromboplastin time in each instance averages 72-75 seconds.

The quantities of partial thromboplastin reagent from each batch are sealed in clear glass vials and stored for 14 months at 5 C. The following table shows the partial thromboplastin time (PPT) in seconds as determined with normal human plasma after 14 months storage. It

3 will be noted that the partial thromboplastin reagent has not lost activity during storage.

Vial PTT, Lot 1 PTT, Lot 2 71. 7 7o. 4 72. 7 70. 5 70. 5 71.0 71. 9 74.0 73. 7 74. 3 72. 0 75. 4 70. 6 70. 9 73. 3 75. 4 70. 0 69.9 71. 2 69. 4 70.8 73.8 75. 4 s1. 2 67.9 70. 1 73. 4 74. 2 s1. 0 74. 1 74. 0 72. 9 72. 0 74. 8 7G. 1 s0. 0 77. 7 79. 2 74. 0 80.3

The invention described and illustrated hereinbefore and secured by these Letters Patent is defined in the following patent claims.

What is claimed is:

1. A reagent for the partial thromboplastin time test comprising ether soluble cephalin derived from brain tissue stabilized by the presence of from about 0.001% to about 0.01% sodium ethylmercurithiolsalicylate.

2. A reagent for the partial thromboplastin time test comprising an ether extract of brain tissue that has been previously extracted with acetone, stabilized by the presence of from about 0.001% to about 0.01% sodium ethylmercurithiolsalicylate.

3. A reagent according to claim 2 wherein the brain tissue is bovine brain tissue.

4. A reagent for the partial thromboplastin time test comprising a suspension of ether soluble cephalin derived from brain tissue in physiological saline, stabilized by the presence of from about 0.001% to about 0.01% sodium ethylmercurithiolsalicylate.

5. A reagent for the partial thromboplastin time test comprising a physiological saline suspension of an ether extract of brain tissue that has previously been extracted with acetone, stabilized by the presence of from about 0.001% to about 0.01% sodium ethylmercurithiolsalicylate.

6. A reagent according to claim 5 wherein the brain tissue is bovine brain tissue.

References Cited in the file of this patent UNITED STATES PATENTS 2,516,216 Kazal July 25, 1960

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2516216 *Jun 24, 1947Jul 25, 1950Sharp & Dohme IncThromboplastin as testing agent
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3980432 *Jul 28, 1975Sep 14, 1976Behringwerke AktiengesellschaftPartial thromboplastin, its use as diagnostic agent and process for preparing it
US4458015 *Mar 19, 1982Jul 3, 1984Boehringer Mannheim GmbhReagent for the optical determination of the blood coagulation
US8617834Dec 15, 2008Dec 31, 2013Siemens Healthcare Diagnostics Products GmbhThromboplastin reagent with long-term stability
EP0107383A1 *Sep 28, 1983May 2, 1984Ortho Diagnostic Systems Inc.Diagnostic activated partial thromboplastin reagent
EP2072624A1 *Nov 28, 2008Jun 24, 2009Siemens Healthcare Diagnostics Products GmbHLong-term stable thromboplastin reagent
Classifications
U.S. Classification435/13, 424/94.64
International ClassificationG01N33/86
Cooperative ClassificationG01N33/86
European ClassificationG01N33/86